Login to Your Account

Clinic Roundup

Wednesday, November 2, 2011

• Aeolus Pharmaceuticals Inc., of Mission Viejo, Calif., reported preliminary results from a pilot study of AEOL 10150 and G-CSF drug Neupogen (filgrastim, Amgen Inc.), which confirmed that AEOL 10150 does not interfere with the positive effects of Neupogen on the hematopoietic syndrome of acute radiation syndrome. The two products in combination were safe and well tolerated.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription